Doctors grade heart-transplant rejection by looking at biopsy tissue under a microscope — but new research shows that similar-looking samples can hide very different biology, which may explain why some patients don’t respond to standard treatment.
Researchers at Vanderbilt Health and the Translational Genomics Research Institute (TGen) applied spatial transcriptomics — a technique that maps gene activity while preserving where each cell sits in the tissue — to repeated biopsy samples from 62 adult and pediatric heart-transplant recipients during and after rejection. The work was published August 10, 2026 in Nature Cardiovascular Research.
What they saw
The team identified 28 immune and heart-cell types whose mix varied across rejection classes, and found substantial molecular differences within the same rejection grade — variation invisible to standard microscopy. Notably, patients who didn’t respond to standard anti-rejection therapy showed baseline T-cell hyperactivation and tissue-remodeling patterns, and certain gene-expression signatures were linked to chronic rejection (cardiac allograft vasculopathy).
Why it matters
Adding this molecular layer to the biopsy could sharpen how doctors diagnose rejection and predict who will respond — distinguishing patients who need only standard care from those who require alternative therapy, and flagging those at risk of long-term complications. It is a research finding, not yet a clinical test, but it points toward more precise management of a life-or-death transplant complication.